Status:
WITHDRAWN
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
Lead Sponsor:
Intarcia Therapeutics
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
Eligibility Criteria
Inclusion
- HbA1c between 7.5% - 10.5%
- on metformin monotherapy
- BMI between 25 \& 45 kg/m2
Exclusion
- on thiazolidinedione, sulfonylureas, DPP-4, exenatide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
- history of pancreatitis
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01455883
Start Date
February 1 2013
End Date
July 1 2014
Last Update
December 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intarcia Therapeutics, Inc
Hayward, California, United States, 94545